Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Chemokines exist in the body at low levels even if

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155565
(Total Views: 602)
Posted On: 06/01/2022 7:48:28 PM
Posted By: MGK_2
Re: ohm20 #124084
Quote:
Chemokines exist in the body at low levels even if an inflammatory response doesn't exist or even when an immune response isn't needed. They also bind to CCR5 under those conditions. When leronlimab binds to CCR5 those chemokines remain unattached and spur the formation of new CCR5 receptors.


If it is not by the cells of the immune system, (CD4, CD8, macrophages, neutrophils, dendrites, natural killer cells, eosinophils, basophils, t helper, t regulators), that chemokines are manufactured, then by what means are chemokines produced?

If the level of chemokine in the serum was sufficient, then why were there insufficient quantites of CCR5 on the surface of CD4 cells in these LH patients with supposedly dead immune systems? Why did it require the binding of LL to CCR5 to induce the cell to manufacture more CCR5 to be expressed on their surface? If the inflammatory chemokine interferon gamma was present, should it not have motivated the CD4 cell to wake the hell up, express more CCR5 and start manufacturing antibodies against the spike proteins?

The only thing that I thought you suggested was that you stated that the chemokines induced CCR5 manufacture and subsequent expression. I liked that idea and went with it. I think you're right in that, but I apparently, in your estimation, I was wrong to think you were right.

This last statement:
Quote:
You also seem to be unaware that cells have life cycles and leronlimab can bind to new cells as they form and the older ones that are already bound with chemokines will die off.


is untrue and not applicable.
If we have to wait for the immune system to regenerate before LL works, this investment is worthless.



(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us